 Cyclerion Therapeutics, Inc. CYCN, a clinical-stage biopharmaceutical company developing soluble guanylate cyclase sGC stimulators for the treatment of serious and orphan diseases, today announced topline results from its Phase 2 proof-of-concept study of praliciguat, a once-daily, orally available systemic sGC stimulator, in diabetic nephropathy. The study did not meet statistical significance on its primary endpoint of reduction in albuminuria from baseline as compared to placebo, measured by urine albumin creatinine ratio UACR, but there was a trend toward improvement across the total intention-to-treat ITT study population. 